The purpose of this study is to compare overall survival rates of colorectal cancer patients
with multi-organ metastases with an indication for first line systemic treatment randomized
for treatment with combination chemotherapy or treatment with combination chemotherapy and
additional maximal tumor debulking including surgical tumor resection, RFA, (DEBIRI-)TACE and
SBRT, depending on best clinical judgement according to a standardized treatment algorithm.
Our hypothesis is that maximal tumor debulking in addition to systemic treatment with
chemotherapy and biologicals will provide an improvement in progression free and overall
survival in this patient group.
Multi-organ Metastatic Colorectal Cancer
Stereotactic Body Radiation Therapy (SBRT),
XELOX regimen according to standard procedures,
FOLFOX regimen according to standard procedures,
radiofrequency ablation (RFA),
transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE),
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.